Skip to main content
. 2015 Jan 8;26(9):2239–2247. doi: 10.1681/ASN.2014050429

Table 3.

Immunohistochemistry results of TMA kidney sections from patients with various underlying clinical conditions

Immunohistochemical Stain Kidney Allografts (n=12) Native Kidneys(n=30) All TMA (n=42)
Recurrent aHUS (n=6) Drug Toxicity (n=2) Rejection (n=4) aHUS (n=11) STEC-HUS (n=1) SLE/APS (n=10) HSCT-TMA (n=6) IgAN (n=1) AAV (n=1)
C4d 6 (100.0) 2 (100.0) 4 (100.0) 8 (72.7) 1 (100.0) 9 (90.0) 6 (100.0) 1 (100.0) 0 (0.0) 37 (88.1)
C5b-9 5 (83.3) 2 (100.0) 3 (75.0) 9 (81.8) 0 (0.0) 8 (80.0) 6 (100.0) 0 (0.0) 0 (0.0) 33 (78.6)
MBL 5 (83.3) 0 (0.0) 1 (25.0) 3 (27.3) 0 (0.0) 2 (20.0) 1 (16.7) 0 (0.0) 0 (0.0) 12 (28.6)
C1q 6 (100.0) 2 (100.0) 4 (100.0) 9/10 (90.0)a 1 (100.0) 8 (80.0) 6 (100.0) 1 (100.0) NAa 37/40 (92.5)a
IgM 6 (100.0) 2 (100.0) 2 (50.0) 6/10 (60)a 1 (100.0) 7 (70.0) 6 (100.0) 1 (100.0) NAa 31/40 (77.5)a

Overall staining in biopsy specimens, defined as the presence of staining along the glomeruli, peritubular capillaries, and/or arterioles. Values are expressed as number (percentage). Drug toxicity refers to TMA in renal allograft in cases caused by toxicity of immunosuppressive therapeutics. Rejection refers to TMA in renal allograft cases during a rejection episode. APS, antiphospholipid syndrome; IgAN, IgA nephropathy; AAV, ANCA-associated vasculitis; NA, not applicable.

a

Two cases had insufficient tissue remaining for IgM and C1q staining. The first case had AAV, and the second case had aHUS.